Evidence map›Paper›PMID 33314411›Full record

ArticleProtein science : a publication of the Protein Society2021

Revisiting the phosphotyrosine binding pocket of Fyn SH2 domain led to the identification of novel SH2 superbinders.

Shuhao Li, Yang Zou, Dongping Zhao, Yuqing Yin, Jingyi Song, Ningning He, Huadong Liu, Dongmeng Qian, Lei Li, Haiming Huang

Abstract read
In one paragraph

Article in Protein science : a publication of the Protein Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shuhao LiCollege of Life Sciences, Qingdao University, Qingdao, China.
Yang ZouSchool of Basic Medicine, Qingdao University, Qingdao, China.
Dongping ZhaoSchool of Basic Medicine, Qingdao University, Qingdao, China.
Yuqing YinDepartment of Antibody Engineering, Shanghai Asia United Antibody Medical Co., Ltd, Shanghai, China.
Jingyi SongSchool of Basic Medicine, Qingdao University, Qingdao, China.
Ningning HeSchool of Basic Medicine, Qingdao University, Qingdao, China.
Huadong LiuCenter for Mitochondrial Biology and Medicine, The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, China.
Dongmeng QianCollege of Life Sciences, Qingdao University, Qingdao, China.
Lei LiSchool of Basic Medicine, Qingdao University, Qingdao, China.
Haiming HuangDepartment of Antibody Engineering, Shanghai Asia United Antibody Medical Co., Ltd, Shanghai, China.ORCID 0000-0003-2942-6091

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Protein engineering through directed evolution is an effective way to obtain proteins with novel functions with the potential applications as tools for diagnosis or therapeutics. Many natural proteins have undergone directed evolution in vitro in the test tubes in the laboratories worldwide, resulting in the numerous protein variants with novel or enhanced functions. we constructed here an SH2 variant library by randomizing 8 variable residues in its phosphotyrosine (pTyr) binding pocket. Selection of this library by a pTyr peptide led to the identification of SH2 variants with enhanced affinities measured by EC50. Fluorescent polarization was then applied to quantify the binding affinities of the newly identified SH2 variants. As a result, three SH2 variants, named V3, V13 and V24, have comparable binding affinities with the previously identified SH2 triple-mutant superbinder. Biolayer Interferometry assay was employed to disclose the kinetics of the binding of these SH2 superbinders to the phosphotyrosine peptide. The results indicated that all the SH2 superbinders have two-orders increase of the dissociation rate when binding the pTyr peptide while there was no significant change in their associate rates. Intriguingly, though binding the pTyr peptide with comparable affinity with other SH2 superbinders, the V3 does not bind to the sTyr peptide. However, variant V13 and V24 have cross-reactivity with both pTyr and sTyr peptides. The newly identified superbinders could be utilized as tools for the identification of pTyr-containing proteins from tissues under different physiological or pathophysiological conditions and may have the potential in the therapeutics.

Indexed as

PhosphotyrosineProto-Oncogene Proteins c-fynRecombinant ProteinsBinding SitesCell Surface Display TechniquesDirected Molecular EvolutionEscherichia coliHumansPeptide LibraryProtein BindingProtein Engineeringsrc Homology DomainsFYN protein, humanPeptide LibraryPhosphotyrosineProto-Oncogene Proteins c-fynRecombinant Proteinsdirected evolutionphage displayphage displayed library construction and selectionprotein-peptide interactionSH2 superbinder

Identifiers

PMID33314411
PMCPMC7888540

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.